TAK-212 / AcuraStem, Takeda - LARVOL DELTA

Orphan Designation: Treatment of amyotrophic lateral sclerosis (FDA) - Date Designated: 10/11/2023

Orphan drug • Amyotrophic Lateral Sclerosis • CNS Disorders

AcuraStem Enters into a License Agreement with Takeda to Advance PIKFYVE Therapeutics (PRNewswire) - "AcuraStem...announced today that it has entered into a license agreement with Takeda to develop and commercialize AcuraStem's PIKFYVE targeted therapeutics including AS-202, an innovative antisense oligonucleotide (ASO) for the treatment of Amyotrophic Lateral Sclerosis (ALS)."

Licensing / partnership • Amyotrophic Lateral Sclerosis